On the other hand high expression of epsin (EPN3) with its well-established role in tumor angiogenesis, conferring worse prognosis in breast and lung cancer, is of high clinical relevance considering the ongoing development of epsin antagonizing therapies. Here, EPN3 is linked to lung carcinoma.